VivoSeq
Oncology

Metastatic Digestive System Neuroendocrine Tumor G1

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Metastatic Digestive System Neuroendocrine Tumor G1 is an early-stage landscape with 4 programs across 3 companies. The most active players are Bristol-Myers Squibb, Novartis, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Cabozantinib

Bristol-Myers Squibb

Everolimus

Novartis

Lutetium Lu 177 Dotatate

Advanced Accelerator Applications

Sunitinib

Pfizer

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSRadiopharmaceutical125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05773274·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)